Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.
At the virtual American Society of Hematology Annual Meeting and Exposition or ASH 2020, Dr. Alexey Danilov of City of Hope was interviewed by CLL Society’s Steve Bloom on his important preclinical research to address one of the significant unmet needs in CLL / SLL/ patients: resistant to venetoclax and/or ibrutinib.
In this interview, our own Dr. Brian Koffman spoke with Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic, and Dr. Sameer Parikh, a hematologist, an oncologist at the Mayo Clinic in Rochester, MN. They discussed why early-stage patients usually do not receive treatment and how that paradigm may be changing with the availability of new targeted therapies and better prognostic markers.
CLL Society Patient Advisory Board CLL Society Patient Advisory Board CLL Society was established to meet the unmet needs of a diverse CLL patient and caregiver community. The Patient Advisory Board
CLL Society Medical Advisory Board CLL Society’s Medical Advisory Board is comprised of leading CLL / SLL experts from across the country. Members generously provide their time and talent to the
At the annual meeting of the American Society of Clinical Oncology (ASCO) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from the ELEVATE R/R study, which is comparing acalabrutinib with ibrutinib head-to-head in high-risk patients with relapsed/refractory CLL and del(17p) or del(11q).
At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from a phase 3 clinical trial testing fixed-duration ibrutinib + venetoclax vs. chlorambucil + obinutuzumab for treating CLL.
CLL Society Board of Directors Solid, generous, grounded, experienced, compassionate, and business savvy, CLL Society’s Board of Directors fortifies CLL Society’s foundation and directs its laser focus towards actualizing our mission.
Our Story, Mission, and Vision Without a story, mission, and vision, our work would have no purpose. Here you will learn what motivates us to work hard every day. Our Story
One click to our most popular content.
